11 matches for your search in the start-up spotlight
rss
First closing of KHAN Technology Transfer Fund II GmbH & Co KG “KHAN-II”
12-Feb-2025
Khanu Fondsverwaltung GmbH (Khanu), a drug discovery focused fund management team, announces the first closing in fundraising for KHAN Technology Transfer Fund II GmbH & Co KG (KHAN-II), the follower fund of KHAN-I (vintage year 2019). As limited partners of KHAN-II, the European Investment Fund ...
KinSea announces first closing of seed financing
01-May-2024
KinSea Lead Discovery AS, a biopharmaceutical start-up pioneering the use of marine bioactives for the treatment of human diseases, announces the successful first closing of its seed financing round. It includes an equity investment from KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I), an ...
"This cooperation has the great potential to lay the groundwork for new, urgently needed therapeutic approaches for AML patients"
13-Sep-2023
RIANA Therapeutics, a spin-off from Vetmeduni Vienna has entered into a collaborative agreement with the Lead Discovery Center GmbH, a renowned organization specialized in translational drug discovery. This partnership marks the first important milestone on RIANA Therapeutics´ mission to discover ...
Promising new approach for the treatment of widespread conditions, including metabolic diseases, obesity, and heart hypertrophy
29-Sep-2022
The KHAN Technology Transfer Fund I (KHAN-I) has committed up to EUR 3 million in milestone-dependent payments to CalTIC, a Dortmund based start-up, for the discovery of a new class of drugs. The start-up builds on a long-term collaboration between the Lead Discovery Center GmbH (LDC), the Max ...
QLi5 Therapeutics Attracts EUR 10 Million in Series A Financing
09-Sep-2022
Qli5 Therapeutics GmbH (QLi5), a German-Korean joint venture developing a new class of proteasome inhibitors, has closed a EUR 10 million series A financing round with an international consortium of investors including SV Investment (Korea), KHAN Technology Transfer Fund I (Germany), Atinum ...
Discovery and development of novel oncology therapies
23-Mar-2021
The Lead Discovery Center GmbH (LDC) and Cumulus Oncology announce the signing of a collaboration agreement enabling the two organisations to accelerate the discovery and development of novel oncology therapies. The collaboration builds on the complementary expertise of both organisations. LDC ...
Launch of Start-up QLi5 Therapeutics
18-Jun-2020
The Lead Discovery Center GmbH (LDC) and the South Korean drug development specialist Qurient have founded QLi5 Therapeutics GmbH, together with their partners, the Max Planck Society (MPG) and Nobel laureate Prof. Huber, emeritus director of the Max Planck Institute for Biochemistry. Dortmund ...
Scientists are developing a procedure whereby vaccines can be absorbed through the skin
14-May-2020
The Max Planck Institute of Colloids and Interfaces in Potsdam and the Technology Transfer Fund KHAN-I are developing a vaccine procedure for SARS-CoV2 together with the Lead Discovery Center in Dortmund. The researchers hope that within the next few years, they will be able to establish immunity ...
Start-up Quench Bio closes USD 50M Series A financing
28-Feb-2020
The Lead Discovery Center GmbH (LDC), the Max Planck Society (MPG) and Max Planck Innovation (MI) announce that their associated company Quench Bio Inc., Cambridge, USA has raised USD 50 million in a Series A financing round. The financing was led by RA Capital Management (RA Capital) and ...
13-Sep-2019
Khanu Management GmbH (Khanu), a drug discovery focused fund management team, announces the successful launch of KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I), based in Dortmund, Germany. The European Investment Fund (EIF, Luxemburg), the Austria Wirtschaftsservice GmbH (Vienna, Austria) ...
